Cato Mork

Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Alopecia Areata: Impact on Patients' Quality of Life and Disease Perception: A Survey-Based Study.

Alopecia Areata: Impact on Patients' Quality of Life and Disease Perception: A Survey-Based Study.

Journal: Acta dermato-venereologica
Published: March 07, 2025

Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients.

Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients.

Journal: Acta dermato-venereologica
Published: September 16, 2024

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.

Journal: The Lancet. Rheumatology
Published: September 14, 2023

New, simplified versus standard photodynamic therapy (PDT) regimen for superficial and nodular basal cell carcinoma (BCC): A single-blind, non-inferiority, randomised controlled multicentre study.

New, simplified versus standard photodynamic therapy (PDT) regimen for superficial and nodular basal cell carcinoma (BCC): A single-blind, non-inferiority, randomised controlled multicentre study.

Journal: PloS one
Published: August 26, 2023

Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy.

Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy.

Journal: Acta dermato-venereologica
Published: August 04, 2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.

Journal: Journal of internal medicine
Published: February 27, 2023

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

Journal: Journal of internal medicine
Published: April 12, 2022

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Journal: JAMA
Published: December 21, 2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Journal: JAMA
Published: May 04, 2021

Infectious Pseudochromhidrosis: A Case Report and Literature Review.

Infectious Pseudochromhidrosis: A Case Report and Literature Review.

Journal: Acta dermato-venereologica
Published: October 16, 2019

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).

Journal: Trials
Published: May 30, 2019

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Journal: Journal of internal medicine
Published: February 15, 2019
Showing 1-12 of 17

Last Updated: 09/26/2026